US FDA sets deadline for removal of CFC epinephrine inhalers
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has set a deadline of 31 December 2011 for manufacturers to take over-the-counter epinephrine metered-dose inhalers containing chlorofluorocarbons off the market. The cut-off date in the final rule on use of ozone-depleting substances; removal of essential-use designation (epinephrine)1 is a year later than the one suggested in the proposed rule that the FDA issued in September 20072,3. This will give manufacturers and users enough time for a properly informed transition to non-CFC alternatives such as prescription albuterol/levalbuterol MDIs that use hydrofluoroalkanes (HFA) as a propellant, the agency believes.
You may also be interested in...
All The Way To The Top: Diversity And Inclusion In Pharma Leadership
Policies, programs and strategies promoting diversity and inclusion are almost as ubiquitous in the pharmaceutical industry these days as environmental commitments. That reflects enormous cultural change over the last few generations, hastened in recent history by initiatives such as MeToo or Black Lives Matter.
HemaQuest expands Phase II remit for HQK-1001 in sickle cell disease
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis withdraws European application for 'personalised' lumiracoxib
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.